Engraftment, Transfusions, and GVHD
| . | BM Group . | PBSC Group . | CD34 Group . | CD34 v BM . |
|---|---|---|---|---|
| Days to | ||||
| ANC >0.5 × 109/L | 20 (11-29)3-150 | 16 (7-27) | 16 (11-37) | P = .08 |
| Platelets >50 × 109/L | 29 (19-150)3-151 | 23 (8-395) | 24 (11-43) | 3-151 |
| No. of RBC units transfused | 6 (0-43) | 9 (0-32) | 9 (3-28) | |
| No. of platelet units transfused | 14 (3-105) | 9 (0-144) | 7 (3-39) | 3-152 |
| Patients receiving granulocytes | 6 | 3 | 1 | |
| Days of discharge3-153 | 38 (14-120) | 38 (13-104) | 38 (19-49) | |
| GVHD grades | ||||
| 0 | 12 | 12 | 8 | |
| I | 24 | 19 | 6 | |
| II | 2 | 7 | 2 | |
| III | 3 | 5 | 0 | |
| IV | 4 | 1 | 1 | |
| Chronic GVHD | ||||
| 0 | 11 | 15 | 14 | |
| Limited | 20 | 14 | 0 | |
| Extensive | 4 | 2 | 0 | |
| Advanced | 0 | 1 | 0 |
| . | BM Group . | PBSC Group . | CD34 Group . | CD34 v BM . |
|---|---|---|---|---|
| Days to | ||||
| ANC >0.5 × 109/L | 20 (11-29)3-150 | 16 (7-27) | 16 (11-37) | P = .08 |
| Platelets >50 × 109/L | 29 (19-150)3-151 | 23 (8-395) | 24 (11-43) | 3-151 |
| No. of RBC units transfused | 6 (0-43) | 9 (0-32) | 9 (3-28) | |
| No. of platelet units transfused | 14 (3-105) | 9 (0-144) | 7 (3-39) | 3-152 |
| Patients receiving granulocytes | 6 | 3 | 1 | |
| Days of discharge3-153 | 38 (14-120) | 38 (13-104) | 38 (19-49) | |
| GVHD grades | ||||
| 0 | 12 | 12 | 8 | |
| I | 24 | 19 | 6 | |
| II | 2 | 7 | 2 | |
| III | 3 | 5 | 0 | |
| IV | 4 | 1 | 1 | |
| Chronic GVHD | ||||
| 0 | 11 | 15 | 14 | |
| Limited | 20 | 14 | 0 | |
| Extensive | 4 | 2 | 0 | |
| Advanced | 0 | 1 | 0 |